A CONNECTION between metal chelation* and at least some types of cancer was suggested by Furst (1963) . Schubert (1966) observed that metal chelation apparently plays a definite role in the cause and treatment of malignancy. The effectiveness of quite a number of metal complex compounds has now been definitely established (Rosenberg, 1971; Williams, 1972; Cleare, 1974; Khan, 1977) . In most instances the compounds are neutral platinum complexes of the type cisPtA2X2 (A = neutral unidentate ligand, such as NH3; X _ charged ligand, such as Cl-). More recently the "platinumpyrimidine blues" have been found to be potent anti-tumour agents (Davidson et al., 1975) . However, little has been reported on the screening of metal chelates as anti-tumour agents.
Certain dialkyldithiophosphate complexes (I) have been reported to display carcinostatic activity in the Walker 256 carcinosarcoma test. When R ethyl, the values for T/C (reduction of tumour in test animal compared to control tumour) for the nickel and palladium chelates were 45 and 16%, respectively, yet the platinum chelate showed little activity. Furthermore, when ethyl was replaced by other alkyl groups, the activity of the nickel and palladium chelates was virtually zero (T/C 100), indicating that minor changes in the ligand markedly affect the activity (Livingstone and Mihkelson, 1970) . Anti-tumour activity has been reported for some metal chelates of derivatives of dithiocarbazic acid, H2NTNHCSSR (Akbar Ali and Livinlgstone, 1974; Das and Livingstone, 1975) . The palladium chelate (II) and the copper chelate (III) were found to display cytostatic activity in the 9KB test-a human epidermoid carcinoma of the nasopharynx. Because of these promising results we, in collaboration with the United States National Cancer Institute, have undertaken a systematic study of the anti-tumour activity of transition metal chelates of Schiff base ligands derived from S-methyldithiocarbazate, H2NNHC( -S) SCH3- We have extended our study to metal chelates of tridentate Schiff bases (VI) derived from S-methyldithiocarbazate. These Schiff bases, by the loss of a proton from their tautomeric form (VII), can behave as singly negatively charged tridentate ligands coordinating to metal ions via the mercapto sulphur, the f-nitrogen, and the pyridine nitrogen atoms.
Complexes of the Schiff bases (VI) with rhodium(III), nickel(II), palladium(II), platinum(II), copper(II), and zinc ( (Basolo and Pearson, 1958) . has enunciated a number of "rules of thumb" relating to the structural chemistry of metal complexes displaying anti-tumour activity; one of these rules is that the metal complex should have one or more active leaving (labile) groups, especially Cl-ion.
This preliminary survey has shown that some transition metal chelates of Schiff bases containing N and S donor atoms possess cytotoxic activity. In particular, several metal chelates of Schiff bases containing the NNS donor grouping display marked activity. It is hoped that further testing of these and other related transition metal complexes may lead to a useful anti-cancer drug.
